TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataIC50: 2.30E+3nMAssay Description:Inhibition of RSV Long fusion protein L138F mutant assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataIC50: 2.56E+3nMAssay Description:Inhibition of RSV Long fusion protein L138F mutant assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after ...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 1.00E+5nMAssay Description:Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 7.90nMAssay Description:Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 221nMAssay Description:Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 140nMAssay Description:Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 5nMAssay Description:Inhibition of human recombinant DGAT1 expressed in Sf9 cells by liquid scintillographyMore data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 12nMAssay Description:Inhibition of DGAT1 in rat adipose tissue assessed as reduction in triacylglycerol synthesisMore data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 10nMAssay Description:Inhibition of DGAT1 in human HuTu80 cellsMore data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 5.42E+3nMAssay Description:Inhibition of DGAT1 in human liver microsomesMore data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 4nMAssay Description:Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 12nMAssay Description:Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 4.30nMAssay Description:Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 2.41E+3nMAssay Description:Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 3nMAssay Description:Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 17nMAssay Description:Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 54nMAssay Description:Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 78nMAssay Description:Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 180nMAssay Description:Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 290nMAssay Description:Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 53nMAssay Description:Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 93nMAssay Description:Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 100nMAssay Description:Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 25nMAssay Description:Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 3nMAssay Description:Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 1.07E+3nMAssay Description:Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 7nMAssay Description:Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 88nMAssay Description:Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 35nMAssay Description:Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 1nMAssay Description:Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 75nMAssay Description:Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 3.40nMAssay Description:Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 28nMAssay Description:Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 2nMAssay Description:Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 5.40nMAssay Description:Inhibition of Respiratory syncytial virus Long fusion glycoprotein infected in Hep2 cells assessed as reduction in virus-induced cytopathic effect af...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 150nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 39nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 41nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 7nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 27nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 14nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 37nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 10nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 14nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 25nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 12nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 540nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 280nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 71nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair
TargetFusion glycoprotein F0(Human respiratory syncytial virus)
Roche Pharma Research And Early Development
Curated by ChEMBL
Roche Pharma Research And Early Development
Curated by ChEMBL
Affinity DataEC50: 26nMAssay Description:Inhibition of RSV Long fusion protein assessed as protection against virus induced cytopathic effect in infected human Hep2 cells after 5 days by CCK...More data for this Ligand-Target Pair